TR200103819T2 - kanser tedavisinde ET743 terkipleri ve kullanımları - Google Patents

kanser tedavisinde ET743 terkipleri ve kullanımları

Info

Publication number
TR200103819T2
TR200103819T2 TR2001/03819T TR200103819T TR200103819T2 TR 200103819 T2 TR200103819 T2 TR 200103819T2 TR 2001/03819 T TR2001/03819 T TR 2001/03819T TR 200103819 T TR200103819 T TR 200103819T TR 200103819 T2 TR200103819 T2 TR 200103819T2
Authority
TR
Turkey
Prior art keywords
compositions
cancer treatment
cancer
treatment
drug
Prior art date
Application number
TR2001/03819T
Other languages
English (en)
Inventor
Louis Misset Jean
Cvitkovic Esteba
Daniel Demetri George
Guzman Cecilia
Jimeno Jose
Twelves Chris
D. Von Hoff Daniel
Bowman Angela
Lopez Lazaro Luis
Original Assignee
Pharama Mar, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9911183.3A external-priority patent/GB9911183D0/en
Priority claimed from GBGB9911346.6A external-priority patent/GB9911346D0/en
Priority claimed from GBGB9918534.0A external-priority patent/GB9918534D0/en
Priority claimed from GBGB9927005.0A external-priority patent/GB9927005D0/en
Priority claimed from GBGB9927106.6A external-priority patent/GB9927106D0/en
Priority claimed from GB0007637A external-priority patent/GB0007637D0/en
Application filed by Pharama Mar, S.A. filed Critical Pharama Mar, S.A.
Publication of TR200103819T2 publication Critical patent/TR200103819T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Insan vücudunda kanser tedavisi için bir ilaç hazirlanmasinda ET743 kullanilir.
TR2001/03819T 1999-05-13 2000-05-15 kanser tedavisinde ET743 terkipleri ve kullanımları TR200103819T2 (tr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9911183.3A GB9911183D0 (en) 1999-05-13 1999-05-13 Treatment of cancers
GBGB9911346.6A GB9911346D0 (en) 1999-05-14 1999-05-14 Treatment of cancers
GBGB9918534.0A GB9918534D0 (en) 1999-08-05 1999-08-05 Treatment of cancers
GBGB9927005.0A GB9927005D0 (en) 1999-11-15 1999-11-15 Treatment of cancers
GBGB9927106.6A GB9927106D0 (en) 1999-11-16 1999-11-16 Cancer treatment
GB0007637A GB0007637D0 (en) 2000-03-29 2000-03-29 Antitumour compound

Publications (1)

Publication Number Publication Date
TR200103819T2 true TR200103819T2 (tr) 2002-04-22

Family

ID=27546594

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03819T TR200103819T2 (tr) 1999-05-13 2000-05-15 kanser tedavisinde ET743 terkipleri ve kullanımları

Country Status (32)

Country Link
US (1) US8119638B2 (tr)
EP (3) EP1716853B9 (tr)
JP (2) JP2002544231A (tr)
KR (1) KR20020019914A (tr)
CN (2) CN1360503A (tr)
AR (1) AR028476A1 (tr)
AT (3) ATE338552T1 (tr)
AU (2) AU777417B2 (tr)
BG (1) BG65680B1 (tr)
BR (1) BR0010531A (tr)
CA (1) CA2373794C (tr)
CY (4) CY1105818T1 (tr)
CZ (1) CZ301482B6 (tr)
DE (4) DE122008000013I1 (tr)
DK (3) DK1702618T3 (tr)
ES (2) ES2272279T3 (tr)
FR (1) FR08C0013I2 (tr)
HU (2) HU229866B1 (tr)
IL (2) IL146434A0 (tr)
LU (1) LU91418I2 (tr)
MX (1) MXPA01011562A (tr)
MY (1) MY164077A (tr)
NL (1) NL300337I2 (tr)
NO (2) NO324564B1 (tr)
NZ (1) NZ515423A (tr)
PL (1) PL198185B1 (tr)
PT (3) PT1716853E (tr)
SI (3) SI1716853T1 (tr)
SK (1) SK287580B6 (tr)
TR (1) TR200103819T2 (tr)
UA (1) UA74782C2 (tr)
WO (1) WO2000069441A1 (tr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
DE60143911D1 (de) * 2000-11-06 2011-03-03 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
US7622458B2 (en) * 2003-11-13 2009-11-24 Pharma Mar, S.A.U. Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
CA2573072A1 (en) * 2004-07-09 2006-01-19 Rafael Rosell Costa Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
CA2582452C (en) * 2004-10-26 2010-09-07 Erard Gilles Pegylated liposomal doxorubicin in combination with ecteinascidin 743
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
AU2007249281A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin
CA2703026A1 (en) * 2007-10-19 2009-04-23 Rafael Rosell Costa Prognostic molecular markers for et-743 treatment
KR20180103965A (ko) 2016-02-04 2018-09-19 지앙수 헨그루이 메디슨 컴퍼니 리미티드 위장관 외용을 위한 트라벡테딘-함유 주사가능한 약학적 조성물 및 그의 제조 방법
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CN112574234B (zh) * 2019-09-27 2022-05-24 江苏恒瑞医药股份有限公司 一种海鞘素衍生物的制备方法
US20230146340A1 (en) 2020-04-15 2023-05-11 Ever Valinject Gmbh Composition comprising trabectedin and an amino acid
US20230226051A1 (en) 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3774435D1 (de) * 1986-06-09 1991-12-12 Univ Pennsylvania Ekteinascidine 729, 743, 745, 759a, 759b and 770.
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
GB8805268D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB9101221D0 (en) * 1991-01-19 1991-02-27 Smithkline Beecham Plc Pharmaceuticals
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5891704A (en) * 1992-11-19 1999-04-06 Anticancer, Inc. Method to produce high levels of methioninase
WO1994026250A1 (en) * 1993-05-14 1994-11-24 Depotech Corporation Method for treating neurological disorders
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
DE69740095D1 (de) * 1996-11-05 2011-02-17 Childrens Medical Center Thalidomide und Dexamethason für die Behandlung von Tumors
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
PT1067933E (pt) * 1998-04-06 2007-11-15 Univ Illinois Ecteinascidinas semi-sintéticas
IL139607A0 (en) * 1998-05-11 2002-02-10 Pharma Mar Sa Metabolites of ecteinascidin 743
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
WO2001077115A1 (en) 2000-04-12 2001-10-18 Pharma Mar, S.A. Antitumoral ecteinascidin derivatives
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (en) * 2000-08-11 2003-10-29 City of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
DE60143911D1 (de) * 2000-11-06 2011-03-03 Pharma Mar Sa Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
WO2002078678A2 (en) 2001-03-30 2002-10-10 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
BR0213424A (pt) * 2001-10-19 2004-12-14 Pharma Mar Sa Uso aperfeiçoado de composto antitumoral na terapia contra câncer
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
US7622458B2 (en) 2003-11-13 2009-11-24 Pharma Mar, S.A.U. Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
CA2545054A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2573072A1 (en) * 2004-07-09 2006-01-19 Rafael Rosell Costa Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
CA2582452C (en) * 2004-10-26 2010-09-07 Erard Gilles Pegylated liposomal doxorubicin in combination with ecteinascidin 743
WO2006046079A1 (en) * 2004-10-29 2006-05-04 Pharma Mar S.A., Sociedad Unipersonal Formulations comprising ecteinascidin and a disaccharide
AU2006318226A1 (en) * 2005-11-25 2007-05-31 Pharma Mar, S.A. Sociedad Unipersonal Use of PARP-1 inhibitors
AU2007249281A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
ES2272279T3 (es) 2007-05-01
ATE375795T1 (de) 2007-11-15
HUP0201187A2 (en) 2002-09-28
DK1176964T3 (da) 2007-01-15
EP1716853B1 (en) 2011-03-09
CN100477993C (zh) 2009-04-15
CN1679631A (zh) 2005-10-12
AU777417B2 (en) 2004-10-14
SI1702618T1 (sl) 2008-02-29
LU91418I9 (tr) 2019-01-02
EP1176964B1 (en) 2006-09-06
IL146434A0 (en) 2002-07-25
BG65680B1 (bg) 2009-06-30
SK16442001A3 (sk) 2002-03-05
CN1360503A (zh) 2002-07-24
FR08C0013I2 (fr) 2009-10-30
NZ515423A (en) 2004-04-30
DK1702618T3 (da) 2008-02-25
CY1112753T1 (el) 2016-02-10
CA2373794C (en) 2005-10-11
PL352931A1 (en) 2003-09-22
CZ20014081A3 (cs) 2002-11-13
AU4597500A (en) 2000-12-05
SK287580B6 (sk) 2011-03-04
IL146434A (en) 2008-03-20
US20070275942A1 (en) 2007-11-29
SI1176964T1 (sl) 2007-02-28
EP1716853A3 (en) 2006-11-15
NO20015516D0 (no) 2001-11-12
DE122008000013I1 (de) 2008-08-07
EP1702618A2 (en) 2006-09-20
EP1176964A1 (en) 2002-02-06
NO20015516L (no) 2002-01-11
PT1716853E (pt) 2011-05-12
MY164077A (en) 2017-11-30
BR0010531A (pt) 2002-06-04
HUS1500001I1 (hu) 2016-08-29
SI1716853T1 (sl) 2011-10-28
JP2002544231A (ja) 2002-12-24
KR20020019914A (ko) 2002-03-13
PT1702618E (pt) 2008-01-11
CY2008007I1 (el) 2009-11-04
EP1176964B8 (en) 2007-10-10
WO2000069441A1 (en) 2000-11-23
EP1716853A2 (en) 2006-11-02
HU229866B1 (en) 2014-10-28
CY1107143T1 (el) 2010-07-28
NL300337I2 (nl) 2008-09-01
AR028476A1 (es) 2003-05-14
PT1176964E (pt) 2007-01-31
DE60036826D1 (de) 2007-11-29
JP2012149095A (ja) 2012-08-09
DK1716853T3 (da) 2011-06-27
CZ301482B6 (cs) 2010-03-17
NL300337I1 (nl) 2008-05-01
DE60030554T2 (de) 2007-09-13
FR08C0013I1 (tr) 2008-05-30
CY1105818T1 (el) 2011-02-02
DE60036826T2 (de) 2008-08-28
ATE338552T1 (de) 2006-09-15
LU91418I2 (fr) 2008-05-13
JP5777562B2 (ja) 2015-09-09
AU2005200180A1 (en) 2005-02-10
EP1702618A3 (en) 2006-12-27
DE60030554T8 (de) 2008-01-10
EP1716853B9 (en) 2011-09-28
US8119638B2 (en) 2012-02-21
CA2373794A1 (en) 2000-11-23
HUP0201187A3 (en) 2002-11-28
MXPA01011562A (es) 2002-07-30
ES2294756T3 (es) 2008-04-01
NO324564B1 (no) 2007-11-19
AU2005200180B9 (en) 2008-05-29
DE60045720D1 (de) 2011-04-21
ATE500830T1 (de) 2011-03-15
PL198185B1 (pl) 2008-06-30
UA74782C2 (uk) 2006-02-15
BG106171A (en) 2002-06-28
NO2008005I1 (no) 2008-06-09
AU2005200180B2 (en) 2007-12-13
EP1702618B1 (en) 2007-10-17
NO2008005I2 (tr) 2010-09-27
DE60030554D1 (de) 2006-10-19
CY2008007I2 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
TR200103819T2 (tr) kanser tedavisinde ET743 terkipleri ve kullanımları
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
NZ544472A (en) Compounds and therapeutical use thereof
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
ATE343969T1 (de) Beschichtete medizinische geräte
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
MY138883A (en) Use of asiatic acid for treatment of cencer
PT1235571E (pt) Utilizacao de melatonina para o tratamento da alopecia androgenetica e difusa do tipo feminino
ATE301999T1 (de) Racecadotril enthaltende trockene pulverformulierung
PL363110A1 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
BG106155A (en) Novel derivatives and analogues of galanthamin
DE60013486D1 (de) Verbindungen
ATE417608T1 (de) Arzneizusammensetzungen enthaltend modafinilverbindungen
IL146132A0 (en) Preparations for the application of anti-infective and/or anti-inflammatory agents to external or internal parts of the human or animal body in functional and cosmetic tissue remodelling and repair treatments
IL118218A (en) Pharmaceutical compositions containing sarcodictyins
EA200200853A1 (ru) Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака
YU29803A (sh) Kombinacija kamptotekina i derivata stilbena za lečenje raka
NZ538926A (en) Medicament containing disorazoles and derivatives thereof for the treatment of benign and malignant tumoral diseases
AU2002214950A1 (en) Determination of the ability of patients to respond to tumour treatment
DK1150981T3 (da) Terapeutisk necleosidforbindelse
GEP20002177B (en) Ointment “Levaskani” for Treatment of Wounds and Burns
GB0007754D0 (en) Proteins and their use for diagnosis and treatment of breast cancer
GB0007265D0 (en) Proteins and their uses for diagnosis and treatment of breast cancer